Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dacomitinib

- PMLiVE

Merck and Pfizer claim second FDA nod for cancer drug Bavencio

Analysts predict it will bring in sales of around $600m by 2020

AstraZeneca AZ

AZ trial adds to pessimism about anti-IL-13 asthma drugs

Firm's IL-13 inhibitor failed to reduce the number of asthma attacks compared to placebo

- PMLiVE

Pfizer launches antibiotic resistance surveillance website

Designed for healthcare professional use ATLAS will cover 60 countries

Pfizer expands Healthcare Hub programme for tech startups

London, Stockholm, Sydney and Toronto hubs open their doors

- PMLiVE

Takeda’s gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy

- PMLiVE

Strong Tagrisso soothes AZ as US sales plummet

Sales decline 34% in the US due to low-cost copies of Crestor

- PMLiVE

Pfizer keeps nose ahead of rivals with new Ibrance approval

FDA licenses new indication for the breast cancer treatment

- PMLiVE

Pfizer resurrects its OTC bid for Viagra in the UK

Confirms MHRA review of new pharmacist-supplied status has begun

- PMLiVE

AZ gets rapid approval in China for Tagrisso

Lung cancer treatment becomes first medicine to pass through the country's Priority Review pathway

- PMLiVE

Merck, Pfizer get first OK for checkpoint inhibitor avelumab

FDA approval for rare skin cancer drug

- PMLiVE

Pfizer launches new antibiotic Zavicefta in UK and Germany

Biopharmaceutical company Pfizer releases MDR antibiotic

- PMLiVE

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links